At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Patrick Schöffski, MD, of University Hospitals Leuven, Leuven, Belgium, discusses the results of a randomised, open-label, multicentre, phase 3 trial of the microtubule dynamics inhibitor, eribulin, versus dacarbazine for the treatment of patients with advanced liposarcoma or leiomyosarcoma.
Phase 3 trial of eribulin versus dacarbazine in leiomyosarcoma and liposarcoma
10th July 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now